The Year's Best Science Fiction: Tenth Annual Collection

SWEF: Notice of AGM

Retrieved on: 
Wednesday, May 17, 2023
Royal Avenue, Belfast, National Storage, Corporate services, London Stock Exchange, Annual, Annual general meeting, Article, London, Annual report, Saint Peter Port, Consolidated, The Year's Best Science Fiction: Tenth Annual Collection, Cryptocurrency, Starwood

In connection with this meeting, copies of the following documents will be posted to shareholders:

Key Points: 
  • In connection with this meeting, copies of the following documents will be posted to shareholders:
    Notice of the Tenth Annual General Meeting; and
    Proxy Form for the Tenth Annual General Meeting.
  • The Notice of the Tenth Annual General Meeting, the Company's Annual Report and Consolidated Financial Statements for the year ended 31 December 2022, which has now been published, and the Company's Articles of Incorporation are all available to view on, and download from, the Company's website at www.starwoodeuropeanfinance.com .
  • Questions and answers will be announced on the London Stock Exchange.
  • The Board will ensure that Shareholders are given as much notice as possible of any proposed changes to the format of the Annual General Meeting.

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Retrieved on: 
Monday, November 14, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Investment, Overalls, Society for Immunotherapy of Cancer, CBC, CAR, Prescription Drug User Fee Act, Hematological Cancer Research Investment and Education Act, NK, Lymphatic system, Cell, ASH, Cancer, Highbridge Capital Management, Letter, CRISPR, Safety, Society, PDUFA, NAM, Center for International Blood and Marrow Transplant Research, The Year's Best Science Fiction: Tenth Annual Collection, Growth, Hematology-Oncology and Stem Cell Transplantation Research Center, Immunotherapy, SOHO, SITC, Database, Patient, Pharmaceutical industry

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.
  • Net loss for the third quarter of 2022 was $17.8 million, compared to a net loss of $23.2 million in the third quarter of 2021.
  • As of September 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $61.3 million.
  • Strengthened financial position: In September 2022, Gamida Cell executed an underwritten public offering raising approximately $20 million, before deducting underwriting discounts, commissions and offering expenses.

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Retrieved on: 
Thursday, September 29, 2022
Science, Stem Cells, Biotechnology, Research, Oncology, Health, Infectious Diseases, Clinical Trials, Hospital, Risk, Therapy, Safety, Infection, The Year's Best Science Fiction: Tenth Annual Collection, COVID-19, Nominal interest rate, Transplant, Twitter, Lymphatic system, FDA, Hematology, Phenotype, LinkedIn, Population, SOHO, Quality of life, Breakthrough therapy, Private Securities Litigation Reform Act, PDUFA, Haematopoiesis, U.S. Securities and Exchange Commission, NK, Patient, Immunotherapy, Facebook, Technology, Instagram, Cell, Standard of care, Hematology-Oncology and Stem Cell Transplantation Research Center, Bone marrow, B cell, Life, Research, Security (finance), Graft-versus-host disease, BLA, SEC, Mortality, NAM, Society, Pharmaceutical industry, EU

These data reinforce our commitment to advance transformational cell therapy research and underscore the potential of our NAM technology platform.

Key Points: 
  • These data reinforce our commitment to advance transformational cell therapy research and underscore the potential of our NAM technology platform.
  • The long-term, durable clinical benefit of omidubicel was observed at three years across a patient population that typically has a poor prognosis.
  • Learn More
    Overall well-being health-related quality of life scores for patients treated with omidubicel demonstrated clinical benefit compared to standard of care.
  • These data suggest clinically meaningful and sustained improvements in physical, functional, and overall well-being compared to umbilical cord blood transplantation.

EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

Retrieved on: 
Wednesday, September 28, 2022
Adult, Apoptosis, Rash, Headache, ASCT, Infection, The Year's Best Science Fiction: Tenth Annual Collection, Lenalidomide, Incidence, Twitter, Bleeding, Food, FSE, ADCC, Diarrhea, Chills, Flushing, LinkedIn, Joint Planning and Development Office, SOHO, MorphoSys, FC, Immunotherapy, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Lymphoid leukemia, B-cell lymphoma, CD19, Hematology-Oncology and Stem Cell Transplantation Research Center, Tafasitamab, Incyte, Bruise, ADCP, NASDAQ, Polyclinic, Fever, Society, Death, DLBCL, Medical imaging, Pharmaceutical industry, Vaccine, Neutropenia

At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.

Key Points: 
  • At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.
  • Of those 27, 23 patients were alive at data cutoff, and 13 remained on treatment, including six who were on treatment for at least 5 years.
  • A complete response was observed in 23 of the 27 patients, including four who were refractory to their primary therapy.
  • A partial response was seen in four patients, two of whom were still on treatment at data cutoff.

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

Retrieved on: 
Wednesday, September 28, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Adult, Apoptosis, Rash, Headache, ASCT, Infection, The Year's Best Science Fiction: Tenth Annual Collection, Lenalidomide, Incidence, Twitter, Bleeding, Food, ADCC, FSE, Diarrhea, Chills, Flushing, LinkedIn, Joint Planning and Development Office, SOHO, FC, Immunotherapy, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Lymphoid leukemia, B-cell lymphoma, CD19, Hematology-Oncology and Stem Cell Transplantation Research Center, Tafasitamab, Incyte, Bruise, ADCP, NASDAQ, Polyclinic, Fever, Oncology, Society, Death, DLBCL, Pharmaceutical industry, Medical imaging, Vaccine, Neutropenia, MorphoSys

At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.

Key Points: 
  • At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.
  • Of those 27, 23 patients were alive at data cutoff, and 13 remained on treatment, including six who were on treatment for at least 5 years.
  • A complete response was observed in 23 of the 27 patients, including four who were refractory to their primary therapy.
  • A partial response was seen in four patients, two of whom were still on treatment at data cutoff.

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

Retrieved on: 
Thursday, September 22, 2022
Therapy, WT1, The Year's Best Science Fiction: Tenth Annual Collection, COVID-19, SLS, Company, SOHO, Memorial Sloan Kettering Cancer Center, Hematology-Oncology and Stem Cell Transplantation Research Center, Terminology, Annual report, Drug development, NASDAQ, GLOBE, SEC, CDK9, GPS, Society, Pharmaceutical industry, Greater China

The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.

Key Points: 
  • The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.
  • Additional presentation details can be found below:
    About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.
  • GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications.

The 2022 BOLD Awards

Retrieved on: 
Tuesday, January 4, 2022
Executive director, The Fillmore, Program, Association, Atomic Data and Nuclear Data Tables, Growth, Glass, Corporation, Game day, ACG, Atomic, BOLD, The Year's Best Science Fiction: Tenth Annual Collection, Health, Sport, Fillmore, GLOBE, Major League Soccer, Management

MINNEAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Game Day Technologies powered by Atomic Data is excited to announce that we have been nominated for the Tenth Annual BOLD Awards, presented by the Minnesota Chapter of the Association for Corporate Growth (ACG.)

Key Points: 
  • MINNEAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Game Day Technologies powered by Atomic Data is excited to announce that we have been nominated for the Tenth Annual BOLD Awards, presented by the Minnesota Chapter of the Association for Corporate Growth (ACG.)
  • The BOLD Awards are designed to honor and recognize innovation, inspirational moves, bold visions and leaders that have made BOLD moves to positively grow, restructure or enhance their companies for the benefit of all stakeholders.
  • Corporate leaders and teams representing the nominees from a group of over 100 stellar organizations will be attending the BOLD Awards on Tuesday, February 22, 2022, starting at 6:00 PM at The Fillmore Minneapolis to network and celebrate.
  • The BOLD Awards will feature finalists in six categories; Not for Profit, Early Stage, 2020 Start Ups, Small & Growing, Middle Market and Large & Established.